Drug Profile
Abequolixron - Inspirna
Alternative Names: Abequolixron zinc; RGX-104; RGX-104 Zinc; SB-742881Latest Information Update: 27 Jun 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer Inspirna
- Class Acetic acids; Amines; Antineoplastics; Chlorobenzenes; Fluorobenzenes; Immunotherapies; Small molecules
- Mechanism of Action Dendritic cell stimulants; Liver X receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Lymphoma; Neuroendocrine tumours; Non-small cell lung cancer; Small cell lung cancer; Solid tumours
Most Recent Events
- 27 Jun 2023 UNC Lineberger Comprehensive Cancer Center in collaboration withAstraZeneca and Rgenix plans a phase I trial for Non-small cell lung cancer (Combination therapy) in USA (NCT05911308)
- 05 Jan 2023 Interim efficacy and adverse events data from a phase Ib/II trial in Non-small cell lung cancer and Small-cell lung cancer released by Inspirna
- 30 Sep 2021 Rgenix is now called Inspirna